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1. Introduction
The alveolar extracellular matrix (ECM) and chronic lung inflammatory diseases, such as
pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), are closely connected.
Pulmonary fibrosis is associated with ECM production, deposition and remodeling. In
contrast, COPD is defined by a loss of the ECM. Matrix metalloproteinases (MMPs) regulate
ECM remodeling, and therefore play an important role in the development of chronic lung
diseases. MMPs constitute a family of endopeptidases that have a common zinc-based active
site. In this chapter, the role of MMPs in pulmonary fibrosis and COPD are discussed, mainly
based on the findings in animal models. The effects of MMPs inhibitor on chronic lung disease
are also herein discussed.
2. Overview
MMPs constitute a family of endopeptidases with a zinc molecule in their active site and a
dependency on Ca2+ for their activity. MMPs are thought to be responsible for the turnover
and degradation of the ECM [1-3]. In the lungs, these proteinases are synthesized and secreted
by diverse cell types, including mesenchymal cells, macrophages, polymorphonuclear cells,
alveolar type II epithelial cells, fibroblasts, smooth muscle cells, the lung parenchyma and
inflammatory cells [4].
Classification
The most commonly used classifications are based partly on the historical assessment of the
substrate specificity of the MMPs, and partly on the cellular localization of the MMPs. They can
be divided into two main groups based on their domain and compartment location: basic
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secreted MMPs (collagenases, gelatinases and stromelysins) and membrane-anchored (the
membrane-type)  MMPs  (MT-MMPs).  The  collagenases  are  capable  of  degrading  triple-
helical fibrillar collagens into distinct 3/4 and 1/4 fragments. These collagens are the major
components of bone, cartilage and dentin, and MMPs are the only known mammalian enzymes
capable of degrading them. The collagenases are MMP-1, -8, -13 and -18. In addition, MMP-14
has also been shown to cleave fibrillar collagen, and there is evidence that MMP-2 is capable of
collagenolysis. The main substrates of the gelatinases are type IV collagen and gelatin, and these
enzymes are distinguished by the presence of an additional domain inserted into the catalytic
domain. This gelatin-binding region is positioned immediately before the zinc-binding motif,
and forms a separate folding unit that does not disrupt the structure of the catalytic domain.
The gelatinases are MMP-2 and MMP-9. The stromelysins display a broad ability to cleave
extracellular matrix proteins, but are unable to cleave the triple-helical fibrillar collagens. The
three canonical members of this group are MMP-3, -10, and -11. All six membrane-type MMPs
(MMP14, -15, -16, -17, -24, and -25) have a furin cleavage site in the pro-peptide, which is a
feature also shared by MMP-11. There are a number of MMPs that do not fit into any of the
traditional groups, such as matrilysins (MMP-7, MMP-26). In addition, MMP-19, enamelysin
(MMP-20), MMP-21, MMP-23A and 23B, MMP-27 and epilysin (MMP-28) have recently been
reported and are still being characterized (Summarized in Table 1).
Structure
To be classified as an MMP, a protein needs to have at least the conserved pro-domain and
catalytic  domain  (Figure  1).  The  pro-domain  of  a  typical  MMP is  80  amino  acids,  and
contains the consensus sequence, PRCXXPD. The exception is MMP23, in which the crucial
cysteine residue is found in a distinct amino acid sequence. The catalytic domain of a typical
MMP contains a zinc ion (Zn2+) in the active site that is ligated to three conserved histi‐
dine  residues  in  the  sequence  HEXXHXXGXXH.  The  glutamic  acid  residue  (E)  in  this
catalytic  motif  provides  the  nucleophile  that  severs  peptide bonds.  The backbone struc‐
tures of the MMP catalytic domain, include a characteristic Met turn on the carboxy side
of the zinc active site, so matrix metalloproteinases have a methionine residue that is always
conserved. This residue is part of a 1,4-β-turn that loops the polypeptide chain beneath the
catalytic zinc ion and forms a hydrophobic base for the zinc-binding site. This is caused by
a conserved methionine residue downstream of the zinc-binding site, which is similar to
those  of  the  astacin-,  reprolysin-  (also  known  as  a  disintegrin  and  metalloproteinase
(ADAMs)) and serralysin-family metalloproteinases.
 
Figure 1. The structure of the MMPs
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Several MMPs have the hemopexin-like C-terminal domain, which is linked to the catalytic
domain by a flexible hinge region. The minimum domain structure is characteristic of matri‐
lysins (MMP-7 and MMP-26). Stromelysin (MMP-3 and MMP-10), collagenases (MMP-1, 8,
Group name Number Substrates
Collagenase-1 MMP-1 Collagen I, II, III, X, Casein
Gelatinase-A MMP-2 CCL7, CXCL12, Collagens IV, V, VII, XI, Gelatin, Fibronectin
Stromelysin-1 MMP-3 E-cadherin, Laminin, Latent TGF-beta, Collagens III, IV, VII, IX, Casein,Fibronectin
Matrilysin MMP-7 Pro-alpha-defensins, Fas L, Latent TNF, Syndecan-1, E-cadherin, Elastin,Collagens IV, Casein, Fibronectin
Collagenase-2 MMP-8 CXCL5, Collagens I, II, III, Casein
Gelatinase-B MMP-9 Zona occludens 1, alpha1-antiproteinase, Latent TGF-beta, Latent VEGF,Fibrin, NG2 proteoglycan, Collagens III, IV, V, Gelatin
Stromelysin-2 MMP-10 Collagens III, IV, V, Casein, Fibronectin
Stromelysin-3 MMP-11 Fibronectin
Metalloelastase MMP-12 Latent TNF, Elastin, Gelatin, Casein
Collagenase-3 MMP-13 Type I, II fibrillar collagen
MT1-MMP MMP-14 ProMMP2, Fibrillar collagens, Fibrin, Syndecan-1, laminin
MT2-MMP MMP-15 Fibrin
MT3-MMP MMP-16 Fibrin, Syndecan-1
MT4-MMP MMP-17 ND
MMP-19 MMP-19 ND
Enamelysin MMP-20 Amelogenin
MMP-21 MMP-21 ND
MMP-23A MMP-23A ND
MMP-23B MMP-23B ND
MT5-MMP MMP-24 ND
MT6-MMP MMP-25 ND
Matrilysin-2 MMP-26 ND
MMP-27 MMP-27 ND
Epilysin MMP-28 ND
ND=Not determined.
Table 1. A list of the currently known MMPs
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13), MMP-12, enamelysin (MMP-20) and MMP-27 have several hemopexin domains.　A
similar domain structure is present in MMP-11, MMP-28 and MMP-21, which have a furin-
like target sequence inserted in their pro-domains. Membrane-type MMPs have membrane-
anchored modules of glycosylphophatidylinositol, which form type I or type II
transmembrane segments. MMP-23A and 23B have an immunoglobulin-like domain. MMP-2
and MMP-9 are secreted MMPs with gelatinolytic activity, and are characterized by the
presence of fibronectin type II modules [1-3].
Regulation
The activation of MMPs can be mediated by other MMPs or proteases, and some are activated
intracellularly by furins. In addition, various chemicals, such as organomercurials, urea, some
detergents and reactive oxygen species, can act as activators of MMPs. Although the healthy
adult lung is not a major source of MMPs, parenchymal cells, such as the airway epithelium,
fibroblasts and smooth muscle have the capacity to express active MMPs following stimulation
by a variety of agents, such as infectious pathogens, environmental toxins, growth factors and
cytokines.
Since MMPs may cause significant host damage, they are tightly regulated. MMPs are
regulated at four main levels: gene transcription, proenzyme activation, activity inhibition and
compartmentalization. First, they are rarely stored, and require gene transcription before
secretion, the exception being neutrophil MMP-8 and -9. Second, MMPs are either secreted as
pro-enzymes that require proteolytic cleavage, or in the case of MT-MMPs, are activated
intracellularly by pro-protein convertases, such as furin. This processing exposes the catalytic
cleft, a mechanism known as the cysteine switch [5]. Third, specific inhibitors of MMPs, the
tissue inhibitors of metalloproteinases (TIMPs), are secreted proteins that bind MMPs in a 1:1
manner to prevent their enzymatic activity [6]. TIMPs comprise a family of four protease
inhibitors (TIMPs 1-4). The balance of MMPs to TIMPs therefore determines the matrix
turnover, where either an excess of MMPs or a deficit of TIMPs may result in excess ECM
degradation. The major endogenous MMP inhibitor in serum is α2-macroglobulin, which
binds MMPs and leads to their clearance by endocytosis. Finally, MMPs can be compartmen‐
talized in close proximity to the cell.
Synthetic MMP inhibitors and clinical implications
A number of rationally-designed MMP inhibitors have shown some promise in the treatment
of pathologies in which MMPs have been implicated. Two major approaches were undertaken
to counterbalance such MMP activity: substrate peptide mimics and small synthetic molecules.
Macpherson and colleagues developed a nonpeptidic hydroxamic acid inhibitor (CGS 27023A)
of the stromelysin group of MMPs, which was orally bioactive and blocked the erosion of
cartilage matrix in an in vivo rabbit model of cartilage degradation [7]. Batimastat, a broad
spectrum MMP inhibitor, showed prolonged survival in an animal model of cancer and some
efficacy in phase I clinical trials, but its development was hindered by its low bioavailability
and limited solubility [8]. Marimastat, a low-molecular-weight substrate peptide-based
hydroximate (inhibitor of MMPs -1, -8, and -13), and prinomastat, based on a sulphonamide-
hydroximate scaffold (inhibitor of MMPs -2, -3, and -13), failed during phase III clinical trials
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for cancer treatment [9]. In addition, cipemastat (Ro 32-3555), an MMP-1-selective inhibitor,
demonstrated limited efficacy in clinical trials. The development of several other MMP
inhibitors was stopped due to their systemic toxicity, a lack of any correlation between the
activity of MMP inhibitors and the MMP levels in the plasma and poor efficacy [10].
Doxycycline, at sub-antimicrobial doses, inhibits MMP activity, and has been used in various
experimental systems for this purpose, such as for recalcitrant recurrent corneal erosions. It is
used clinically for the treatment of periodontal disease, and is the only MMP inhibitor that is
widely available clinically. Minocycline, another tetracycline antibiotic, has also been shown
to inhibit MMP activity. For example, tetracyclines, which are used in the treatment of arthritis,
have been shown to reduce the activity of MMPs -1, -2 and -9 [11].
3. The inflammatory process
The main activity of MMPs is considered to be the degradation of the ECM. However, matrix
degradation is neither the sole function, nor the main function, of these proteinases. Recent
findings indicate that MMPs play an important role in the regulation of cytokine and chemo‐
kine release and activation, which are key steps in the immune response [2, 3, 12-14]. For
example, MMP-1,-2, -3, -7, -9, and -12 are able to process pro-tumor-necrosis factor (TNF)-α
into soluble active TNF-α. MMP-2, -3 and -9 also have the ability to cleave interleukin (IL)-1β,
generating a more active form. MMP-9 controls the IL-2-dependent proliferation of T lym‐
phocytes. MMP-8, -13 and -14 can cleave IL-8 to generate truncated forms with increased
activity. Therefore, inflammatory cytokines and MMPs are interconnected.
An essential pro-inflammatory mediator that is regulated by metalloproteinase activity is TNF,
which is produced as a 26-kDa membrane-associated protein (proTNF) that is cleaved by TNF-
converting enzyme (TACE) into a soluble 17.5-kDa cytokine. Because synthetic metallopro‐
teinase inhibitors block this cleavage, it was suggested that TACE was an MMP. However,
when the convertase activity was purified and cloned, TACE was found to be identical to
ADAM17 [15, 16]. The cleavage of proTNF by ADAM17 is specific [17]. Since the release of
active TNF is reduced by 90% in cells derived from ADAM17-deficient mice, ADAM17 seems
to be the principal physiological TNF-converting enzyme in vivo. Several MMPs (including
MMP-1, -2, -3, -9 and -17) can process proTNF to its active form in vitro [18, 19]. MMP-7 and
MMP-12 also activate proTNF in macrophages. The high-level release of TNF in response to
bacteria and toxic shock by MMP-7 and MMP-12 processing might elicit the constitutive release
of TNF from macrophages that is required for common functions, such as tissue resorption
and resolution, in response to injury.
Similarly, IL-1, a potent pro-inflammatory cytokine, requires proteolytic processing for
activation, a process attributed to the IL-1-converting enzyme (ICE, caspase-1). Although the
function of ICE had been well established in vitro, studies using ICE-deficient mice provided
evidence of other mechanisms of IL-1 activation [20]. It was subsequently discovered that
MMP-2, -3 and -9 can cleave and activate the IL-1 precursor [21]. Furthermore, after activating
IL-1, MMP-3 degrades the biologically active cytokine [21], which can also be inactivated in
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vitro by MMP-1, -2 and -9 [22]. These data indicate a dual role for MMPs in the biphasic
modulation of inflammatory-mediator activity. MMPs are involved in both the activation and
inactivation of these inflammatory molecules.
Moreover, several studies have indicated that MMPs can either directly or indirectly affect the
activity interferon-γ [23], vascular endothelial growth factor [24], epidermal growth factors
[25], fibroblast growth factors [26] and transforming growth factor (TGF)-β. As shown using
TGF-β-deficient mice, this cytokine functions to restrain mononuclear inflammation [27-29].
In both cells and tissue-explant models, MMP-3 [30], MMP-9 [31] and MMP-14 [32] have been
shown or suggested to activate a proportion of the total TGF-β.
Lopez-Boado et al. reported a 25-fold induction of MMP-7 in lung epithelial cells following
infection with Escherichia coli [33] and Pseudomonas aeruginosa, [34] which could explain the
upregulation of this enzyme in the airway of cystic fibrosis patients who are commonly
infected with these bacteria. It has also been shown that proinflammatory cytokines, such as
IL-1β and TNF-α, upregulate the expression of MMP-9 in human airway epithelial cells
following a one-day treatment [35].
4. Pulmonary fibrosis and MMPs
Lung inflammation is deeply associated with the process of pulmonary fibrosis. MMP-9 was
observed in alveolar macrophages from idiopathic pulmonary fibrosis patients [36] and in the
bronchoalveolar lavage (BAL) fluid from patients with bleomycin-induced pulmonary fibrosis
[37, 38]. An mRNA study also supported that the activation of MMP-2 and MMP-9, both
gelatinases, is involved in pulmonary fibrosis [39]. The function of other MMPs, such as
collagenases or stromelysins, in pulmonary fibrosis is still unclear, despite their importance in
ECM deposition. Edwards and colleagues reported that mast cells harvested from the tissues
of patients with interstitial lung diseases demonstrated the expression of MMP-1. MMP-1 has
thus been reported to be important for controlling fibrogenesis in humans [40]. Although the
existence of MMP-1 is unclear in rodents [41], other collagenases, such as MMP-13, have been
detected [42]. Similarly, collagenase activity has been observed after bleomycin administration
[37]. An immunohistochemical analysis demonstrated that MMP-13 expression was present
after bleomycin administration [43]. However, other researchers have reported that the MMP-9
(gelatinase B), MMP-3 (stromelysin-1) and interstitial collagenase gene expression did not
significantly change after bleomycin administration [44].
5. Therapeutic trials for pulmonary fibrosis
As mentioned previously, doxycycline inhibits MMP activity. We demonstrated that the early
administration of doxycycline inhibited early inflammation and resulted in an inhibition of
the development of pulmonary fibrosis through the inhibition of early inflammation [45].
However, doxycycline did not affect established pulmonary fibrosis. A MMPs inhibitor,
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batimastat, was reported to attenuate pulmonary fibrosis in mice [38]. Batimastat inhibited
both MMP-2 and TIMP-1, and resulted in the attenuation of pulmonary fibrosis. In contrast, a
MMPs inhibitor, CGS27023A, blocked the anti-fibrotic MMPs and resulted in an augmentation
of the ECM [43].
MMPs play an important role in the development of pulmonary fibrosis. However, there are
conflicting hypotheses regarding whether MMPs have anti-fibrotic properties [46]. Research‐
ers should focus on when and what type of MMPs inhibitor(s) should be used for pulmonary
fibrosis.
6. COPD and MMPs
Both alveolar and bronchial inflammation have been shown to be present in human COPD.
Hence, chronic inflammation contributes to the development of COPD through the destruction
of alveoli and the induction of MMPs. Recently, the role of MMPs has been given increasing
attention as a possible mechanism underlying the development of pulmonary emphysema.
Additionally, the inflammatory cells invading the lung during the course of COPD are also a
major source of different MMPs. It has been shown that neutrophils and macrophages are the
predominant inflammatory cells in the lungs of COPD patients [47, 48].
Lipopolysaccharide (LPS) is a strong proinflammatory compound present in the cell wall
of gram-negative bacteria. Acute LPS instillation induces apoptotic cell death in bronchial
epithelial cells at early time points, and neutrophil apoptosis in the lungs at later time points
[49, 50], and this is associated with the production of MMPs, mainly gelatinase [51]. LPS
leads  to  the  recruitment  of  neutrophils  and  macrophage  activation  with  concomitant
airspace enlargement [52, 53]. Although humans tolerate bacterial pneumonia without any
residual  emphysema,  the  chronic  instillation  of  LPS  was  found  to  induce  COPD-like
changes.  Bacterial  endotoxin  was  demonstrated  to  be  present  in  high  concentrations  in
tobacco  (approximately  20  µg/cigarette),  and  bioactive  LPS  could  be  detected  in  both
mainstream and sidestream cigarette smoke (approximately 0.12-0.2 µg/cigarette) [54, 55].
Repetitive LPS instillation for 12 weeks led to COPD-like changes [56]. This mouse model
mimicked several important pathological changes that are observed in COPD patients. These
mice demonstrated goblet cell metaplasia in the larger airways, thickening of the airway
walls and irreversible alveolar enlargements [57]. It is well known that LPS induces TNF-
α. TNF-α overexpression in mice has been reported to have diverse effects, including the
induction of pulmonary emphysema and pulmonary fibrosis. At first, the overexpression
of TNF-α in the lungs of mice was thought to lead to pulmonary fibrosis [58, 59]. In contrast,
TNF-α  overexpressing  mice  bred  in  Denver  demonstrated  pulmonary  emphysema  [60].
Chronic inflammation, a reduced elastic recoil, a huge lung size and an activation of MMPs
(mainly MMP-2 and MMP-9) were all observed in these mice, along with a progression of
pulmonary hypertension [61]. In addition, this mouse model was insensitive to fibrogene‐
sis factor, bleomycin and TGF-β [62]. Many evidence have demonstrated that TNF-α plays
a critical  role in smoking-related emphysema [63].  Taking these findings into considera‐
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tion, TNF-α is considered to play a crucical role in the development of COPD and MMPs,
mainly MMP-2 and MMP-9 is associated with the COPD pathogenesis.
Several transgenic mouse strains with targeted expression of cytokines show COPD-like
lesions, such as airspace enlargement, thickening of the airway walls and subepithelial fibrosis
without any exposure to a specific agent [64, 65]. An overexpression of IL-13 in the murine
lung caused an asthma-like eosinophil- and lymphocyte-rich inflammation, goblet cell
hyperplasia, airway fibrosis and alveolar enlargement [66, 67]. The induced overexpression of
interferon (IFN)-γ in the lungs of mice caused a phenotype mimicking human COPD [68]. In
these models, the overexpression of these inflammatory cytokines was associated with an
increased expression of MMPs (mainly gelatinase) and cysteine proteases, including cathe‐
psins. Similarly, macrophage colony stimulating factor (M-CSF)-deficient mice, surfactant
protein D (SP-D)-deficient mice and integrin αvβ6-deficient mice also develop air space
enlargement [69-71]. The macrophages of SP-D-deficient mice have increased oxidant pro‐
duction, which activates nuclear factor (NF)-κB and subsequently leads to MMP expression
[72]. NF-kB is also well known to be a transcription factor involved in the induction of TNF-
α. Inflammation and MMPs activation (mainly gelatinase) contribute to the development of
COPD.
Another mechanism for COPD involves macrophage elastase (MMP-12). MMP-12 is nearly
undetectable in healthy macrophages, while MMP-12 is expressed in the alveolar macrophages
of human cigarette smokers. Of note, MMP-12 knockout mice did not develop emphysema in
response to long-term cigarette smoke exposure [73, 74]. MMP-12 knockout mice also failed
to recruit macrophages into their lungs in response to cigarette smoke. Neutrophil elastase-
deficient mice were significantly protected from the development of pulmonary emphysema
after cigarette smoke exposure [75]. Mice that constitutively overexpress human MMP-1
develop spontaneous air space enlargement, showing that MMP-1 can drive pulmonary
destruction [76]. Since that report, numerous transgenic mouse models have been developed,
in which emphysema-like changes are induced. The absence of MMP inhibitors can also result
in abnormal pulmonary matrix turnover, as TIMP-3 deficient mice spontaneously develop air
space enlargement at two weeks of age [77].
The functional importance of MMP activity in these models was confirmed by crossing
emphysema-developing mice with MMP-knockout mice. For example, in the IL-13 overex‐
pression model, a deficiency of MMP-9 or MMP-12 results in reduced pathological changes
and less respiratory failure [78]. Similarly, crossing integrin αvβ6-deficient mice with MMP-12-
deficient mice prevents the development of age-related emphysema [79].
MMPs seem to be strongly related to the development of COPD [80]. In a clinical study, there
were increases in the pulmonary expression of MMP -1 [81], MMP-2 [82], MMP-8 [83], MMP
-9 [84], MMP-12 [85] and MMP-14[82] in COPD patients. For example, Finlay and colleagues
detected collagenase activity in BAL fluid samples from 100% of emphysematous patients but
in only 10% of smoking controls; and MMP-9 was present in 60% of patients compared to 20%
in the control group [84]. Segura-Valdez and colleagues showed a significant upregulation of
MMPs -1, -2, -8, and -9 in the BAL fluid samples obtained from COPD patients [86]. In another
study, Imai and colleagues reported the detection of MMP-1 mRNA by in situ hybridization,
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and also found protein expression and enzymatic activity in the lung samples of patients with
emphysema. However, there was no MMP-1 detected in the lungs of normal control subjects
[81]. Additionally, Ohnishi and colleagues documented a more than three-fold increase in the
level of MMP-2 protein and activation in lung samples from emphysematous patients
compared to subjects in the control group [82]. Another study reported an increase in the
MMP-9 protein level in 40% of COPD patients compared to healthy subjects. The location of
the MMP-9 expression was confirmed by an immunohistochemical analysis to be in the
bronchial epithelium and submucosal areas [87]. Furthermore, an extracellular MMP inducer,
called basigin, a member of the immunoglobulin G (IgG) superfamily, were increased in
smokers' BAL fluid samples [88]. The extracellular MMP inducer was prominent in the
bronchial glands, bronchial epithelium and alveolar macrophages. An increase in the level of
MMP-9 has also been reported in the sputum of patients with chronic bronchitis compared to
control subjects [89].
MMP-9 and MMP-12 play key roles in the development of COPD in mice. However, studies
in patients suggest that the spectrum of MMPs in human disease may differ significantly from
these models. Studies of MMP activity demonstrate divergent results at different stages of
disease evolution, and lead to controversy about which MMPs are critical in pulmonary disease
in humans. Taking the data from both clinical and animal studies into consideration, MMP-9
is the most compelling molecule related to the development of COPD. In contrast, MMP-12 is
essential for the cigarette smoke-induced pathology in the mouse, but may not be equally
critical in human disease.
7. Therapeutic trials for COPD
MMP inhibition could be a promising candidate therapy for COPD. In fact, a MMP inhibitor,
GM6001, has been reported to block the emphysematous changes associated with methyl‐
prednisolone-induced emphysema in rats [90]. However, past experiences, including our own
study, have shown that a broad spectrum MMP inhibitor would be of limited benefit [91-93].
In fact, our preliminary study using CGS27023A, an MMP inhibitor, or doxycycline, did not
improve the COPD in mice with TNF-α overexpression (unpublished data). Nonselective
MMP inhibitors, such as marimastat, have major side effects. Isoenzyme-selective inhibitors
or inhaled delivery may be needed. A dual MMP9–MMP12 inhibitor (AZ11557272) was shown
to prevent emphysema, small airway fibrosis and inflammation in guinea pigs that were
exposed to cigarette smoke over a six‑month period [94], but its clinical development has now
been stopped for some unknown reason. MMP-9 is potentially a good target for patients with
emphysema, but progress in the development of drugs targeting MMP-9 has been disappoint‐
ing, because it has proved to be difficult to discover safe and selective MMP-9 inhibitors [93].
A more sophisticated approach is therefore required in the future.
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8. Conclusion
There is a controversy concerning the role of MMPs in the development of chronic inflamma‐
tory lung diseases. There were two possible but conflicting roles of MMPs: promoting the
deposition of the ECM by facilitating fibroblast migration, or degenerating the ECM. MMPs
play important roles in the degradation of the ECM and recovery from lung damage. Similar
to inflammation, MMPs activation was observed in both pulmonary fibrosis and COPD. The
role of MMPs in inflammatory lung diseases is therefore complex. The different MMPs show
variations in terms of their effecting depending on different condition. In addition, MMP
inhibitors appear to work in different ways. More precise and specific studies of both the
proteins themselves and their specific inhibitors will be needed in the future. Moreover, there
are discrepancies between mice and humans. Novel therapeutic agents targeting MMPs for
use against chronic inflammation are currently under development, and more will likely be
developed as more is learned about the MMPs and their functions. This information is
summarized in Figure 2.
 
Figure 2. A schematic drawing of the relationship between MMPs and lung injury.
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